Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 6 | 2021 | 215 | 0.790 |
Why?
|
| Mycoses | 4 | 2012 | 46 | 0.580 |
Why?
|
| Immunocompromised Host | 3 | 2021 | 107 | 0.450 |
Why?
|
| Ascomycota | 1 | 2012 | 12 | 0.400 |
Why?
|
| Bursitis | 1 | 2012 | 17 | 0.400 |
Why?
|
| Knee Injuries | 1 | 2012 | 47 | 0.390 |
Why?
|
| Anti-Bacterial Agents | 6 | 2019 | 787 | 0.370 |
Why?
|
| Kidney Transplantation | 2 | 2017 | 315 | 0.360 |
Why?
|
| Antitubercular Agents | 2 | 2012 | 82 | 0.320 |
Why?
|
| Tuberculosis | 2 | 2012 | 295 | 0.320 |
Why?
|
| Patient Compliance | 1 | 2009 | 358 | 0.270 |
Why?
|
| Imipenem | 2 | 1997 | 4 | 0.250 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2020 | 203 | 0.240 |
Why?
|
| Opportunistic Infections | 2 | 2017 | 30 | 0.230 |
Why?
|
| Organ Transplantation | 2 | 2019 | 54 | 0.220 |
Why?
|
| Pleural Effusion | 2 | 2020 | 39 | 0.200 |
Why?
|
| Ganciclovir | 1 | 2002 | 18 | 0.200 |
Why?
|
| Lithiasis | 1 | 2002 | 1 | 0.200 |
Why?
|
| Actinomycosis | 1 | 2002 | 3 | 0.200 |
Why?
|
| Hemoptysis | 1 | 2002 | 8 | 0.200 |
Why?
|
| Bronchial Diseases | 1 | 2002 | 12 | 0.190 |
Why?
|
| Cytomegalovirus Infections | 1 | 2002 | 66 | 0.190 |
Why?
|
| Histoplasmosis | 1 | 2002 | 24 | 0.190 |
Why?
|
| Bronchi | 1 | 2002 | 77 | 0.190 |
Why?
|
| Antifungal Agents | 3 | 2020 | 127 | 0.180 |
Why?
|
| Lung Diseases | 2 | 2018 | 176 | 0.170 |
Why?
|
| Ampicillin | 2 | 1997 | 12 | 0.170 |
Why?
|
| DNA Polymerase III | 1 | 2000 | 28 | 0.170 |
Why?
|
| Gram-Positive Bacteria | 1 | 2000 | 36 | 0.170 |
Why?
|
| Strongyloides stercoralis | 1 | 2020 | 12 | 0.170 |
Why?
|
| Uracil | 1 | 2000 | 30 | 0.170 |
Why?
|
| Strongyloidiasis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2020 | 13 | 0.170 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 79 | 0.160 |
Why?
|
| Antiviral Agents | 1 | 2002 | 322 | 0.160 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2019 | 8 | 0.160 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2019 | 16 | 0.160 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 373 | 0.150 |
Why?
|
| Critical Care | 2 | 2020 | 393 | 0.140 |
Why?
|
| Drug Therapy, Combination | 4 | 2000 | 463 | 0.140 |
Why?
|
| Mycobacterium haemophilum | 1 | 2017 | 5 | 0.140 |
Why?
|
| Mycobacterium Infections | 1 | 2017 | 16 | 0.140 |
Why?
|
| Thienamycins | 1 | 1997 | 1 | 0.140 |
Why?
|
| Tobramycin | 1 | 1997 | 7 | 0.130 |
Why?
|
| Penicillins | 1 | 1997 | 30 | 0.130 |
Why?
|
| Gentamicins | 1 | 1997 | 25 | 0.130 |
Why?
|
| Lung | 1 | 2002 | 942 | 0.130 |
Why?
|
| Phylogeny | 2 | 2021 | 375 | 0.130 |
Why?
|
| Pseudomonas aeruginosa | 1 | 1997 | 108 | 0.130 |
Why?
|
| Humans | 25 | 2021 | 62915 | 0.130 |
Why?
|
| Crohn Disease | 1 | 2017 | 111 | 0.130 |
Why?
|
| Endocarditis, Bacterial | 2 | 1993 | 36 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 728 | 0.120 |
Why?
|
| Middle Aged | 10 | 2021 | 17403 | 0.110 |
Why?
|
| Staphylococcus | 2 | 1999 | 17 | 0.110 |
Why?
|
| DNA, Bacterial | 2 | 2012 | 267 | 0.110 |
Why?
|
| Rickettsiaceae | 1 | 1993 | 1 | 0.100 |
Why?
|
| Rickettsiaceae Infections | 1 | 1993 | 5 | 0.100 |
Why?
|
| Molecular Sequence Data | 2 | 2012 | 1997 | 0.100 |
Why?
|
| Cryptococcosis | 2 | 2008 | 79 | 0.100 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2004 | 111 | 0.090 |
Why?
|
| Tissue Donors | 1 | 2012 | 152 | 0.090 |
Why?
|
| Male | 12 | 2021 | 29587 | 0.090 |
Why?
|
| HLA-B Antigens | 1 | 2010 | 13 | 0.090 |
Why?
|
| Genes, MHC Class I | 1 | 2010 | 27 | 0.090 |
Why?
|
| Bronchoscopy | 2 | 2020 | 87 | 0.090 |
Why?
|
| Skin Diseases, Infectious | 1 | 1990 | 12 | 0.090 |
Why?
|
| HIV-1 | 2 | 2010 | 719 | 0.090 |
Why?
|
| Peritonitis | 1 | 1990 | 36 | 0.090 |
Why?
|
| Massachusetts | 2 | 2009 | 2062 | 0.080 |
Why?
|
| Ultrasonography | 1 | 2012 | 479 | 0.080 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 377 | 0.080 |
Why?
|
| Colitis | 1 | 1990 | 77 | 0.080 |
Why?
|
| Isoniazid | 1 | 2009 | 11 | 0.080 |
Why?
|
| Rifampin | 1 | 2009 | 25 | 0.080 |
Why?
|
| Enterococcus faecium | 2 | 2020 | 7 | 0.080 |
Why?
|
| Amphotericin B | 1 | 2008 | 23 | 0.080 |
Why?
|
| HIV Infections | 2 | 2010 | 965 | 0.080 |
Why?
|
| Antigen Presentation | 1 | 2010 | 237 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2008 | 55 | 0.070 |
Why?
|
| Oxazoles | 1 | 1988 | 10 | 0.070 |
Why?
|
| Streptococcus | 1 | 1988 | 17 | 0.070 |
Why?
|
| Triazoles | 1 | 2008 | 56 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 968 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 205 | 0.060 |
Why?
|
| Candida | 2 | 2020 | 38 | 0.060 |
Why?
|
| Treatment Outcome | 4 | 2009 | 5606 | 0.060 |
Why?
|
| Time Factors | 3 | 2002 | 3748 | 0.060 |
Why?
|
| Student Health Services | 1 | 2004 | 6 | 0.060 |
Why?
|
| Liver | 1 | 2009 | 847 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2018 | 1293 | 0.060 |
Why?
|
| Communicable Disease Control | 1 | 2004 | 42 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 2156 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2004 | 136 | 0.050 |
Why?
|
| Adult | 6 | 2009 | 16662 | 0.050 |
Why?
|
| Injections, Intravenous | 1 | 2002 | 156 | 0.050 |
Why?
|
| Aged | 4 | 2020 | 14271 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2002 | 102 | 0.050 |
Why?
|
| Superinfection | 1 | 2002 | 10 | 0.050 |
Why?
|
| Granuloma | 1 | 2002 | 41 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2002 | 91 | 0.050 |
Why?
|
| Retrospective Studies | 3 | 2020 | 6555 | 0.050 |
Why?
|
| Female | 6 | 2017 | 32579 | 0.050 |
Why?
|
| Incidence | 3 | 2012 | 1374 | 0.050 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 155 | 0.050 |
Why?
|
| Calcinosis | 1 | 2002 | 83 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2002 | 368 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2002 | 223 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 516 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2021 | 65 | 0.040 |
Why?
|
| Mycophenolic Acid | 1 | 2021 | 68 | 0.040 |
Why?
|
| Enterococcus | 1 | 2000 | 10 | 0.040 |
Why?
|
| Candidiasis, Invasive | 1 | 2020 | 9 | 0.040 |
Why?
|
| Thiabendazole | 1 | 2020 | 3 | 0.040 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2020 | 14 | 0.040 |
Why?
|
| Daptomycin | 1 | 2020 | 9 | 0.040 |
Why?
|
| Blood Cell Count | 1 | 2020 | 33 | 0.040 |
Why?
|
| Antiparasitic Agents | 1 | 2020 | 9 | 0.040 |
Why?
|
| Survival Rate | 1 | 2002 | 845 | 0.040 |
Why?
|
| Ivermectin | 1 | 2020 | 24 | 0.040 |
Why?
|
| HIV Long Terminal Repeat | 1 | 2000 | 12 | 0.040 |
Why?
|
| Abdomen | 1 | 2020 | 92 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 115 | 0.040 |
Why?
|
| Pneumonia, Staphylococcal | 1 | 1999 | 11 | 0.040 |
Why?
|
| Methicillin Resistance | 1 | 1999 | 23 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 34 | 0.040 |
Why?
|
| Aged, 80 and over | 1 | 2009 | 5408 | 0.040 |
Why?
|
| Staphylococcus aureus | 1 | 2000 | 177 | 0.040 |
Why?
|
| Young Adult | 1 | 2009 | 4646 | 0.040 |
Why?
|
| Candidiasis | 2 | 2008 | 51 | 0.040 |
Why?
|
| Anti-HIV Agents | 1 | 2000 | 154 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1997 | 863 | 0.040 |
Why?
|
| Pulmonary Atelectasis | 1 | 2018 | 11 | 0.040 |
Why?
|
| Streptomycin | 1 | 1997 | 14 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2018 | 30 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2020 | 251 | 0.040 |
Why?
|
| Drug Resistance, Multiple | 1 | 1997 | 34 | 0.030 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1997 | 30 | 0.030 |
Why?
|
| Agar | 1 | 1997 | 4 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 1999 | 297 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 404 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 369 | 0.030 |
Why?
|
| Preoperative Care | 1 | 2018 | 190 | 0.030 |
Why?
|
| Fetal Blood | 1 | 1997 | 73 | 0.030 |
Why?
|
| Culture Media | 1 | 1997 | 79 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1997 | 127 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 1997 | 115 | 0.030 |
Why?
|
| Zinc | 1 | 1997 | 92 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 1997 | 487 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1732 | 0.030 |
Why?
|
| Temperature | 1 | 1997 | 309 | 0.030 |
Why?
|
| Viral Load | 2 | 2010 | 231 | 0.030 |
Why?
|
| Base Sequence | 2 | 2000 | 1333 | 0.030 |
Why?
|
| Pneumonia | 1 | 2018 | 289 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2002 | 1594 | 0.030 |
Why?
|
| Drug Stability | 1 | 1994 | 143 | 0.030 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1994 | 230 | 0.030 |
Why?
|
| Drug Resistance, Microbial | 2 | 1997 | 48 | 0.030 |
Why?
|
| Base Composition | 1 | 1993 | 30 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 1993 | 85 | 0.030 |
Why?
|
| RNA, Bacterial | 1 | 1993 | 73 | 0.020 |
Why?
|
| Lactobacillus acidophilus | 1 | 1992 | 1 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 3263 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 1997 | 1348 | 0.020 |
Why?
|
| Living Donors | 1 | 2012 | 77 | 0.020 |
Why?
|
| Fatty Acids | 1 | 1993 | 200 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 455 | 0.020 |
Why?
|
| HLA-C Antigens | 1 | 2010 | 3 | 0.020 |
Why?
|
| HIV Long-Term Survivors | 1 | 2010 | 8 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 9 | 0.020 |
Why?
|
| HIV Antigens | 1 | 2010 | 18 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 131 | 0.020 |
Why?
|
| Immune Tolerance | 1 | 1990 | 175 | 0.020 |
Why?
|
| Amino Acids | 1 | 2010 | 146 | 0.020 |
Why?
|
| Alleles | 1 | 2010 | 449 | 0.020 |
Why?
|
| Phenotype | 1 | 1993 | 1196 | 0.020 |
Why?
|
| Norfloxacin | 1 | 1988 | 2 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2010 | 359 | 0.020 |
Why?
|
| Oxazolidinones | 1 | 1988 | 13 | 0.020 |
Why?
|
| Aspergillosis | 1 | 2008 | 40 | 0.020 |
Why?
|
| Ciprofloxacin | 1 | 1988 | 25 | 0.020 |
Why?
|
| Gram-Negative Bacteria | 1 | 1988 | 57 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 1988 | 43 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 491 | 0.020 |
Why?
|
| Safety | 1 | 2008 | 145 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2010 | 776 | 0.020 |
Why?
|
| Risk Factors | 1 | 2018 | 5311 | 0.020 |
Why?
|
| Cryptococcus neoformans | 1 | 2008 | 148 | 0.020 |
Why?
|
| Logistic Models | 1 | 2010 | 1269 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2008 | 736 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2010 | 1147 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 1160 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2010 | 674 | 0.020 |
Why?
|
| Tuberculin Test | 1 | 2004 | 9 | 0.010 |
Why?
|
| Immunity, Innate | 1 | 2010 | 796 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 2547 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2004 | 161 | 0.010 |
Why?
|
| Universities | 1 | 2004 | 158 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2004 | 289 | 0.010 |
Why?
|
| Animals | 1 | 2020 | 20642 | 0.010 |
Why?
|
| Prevalence | 1 | 2004 | 1360 | 0.010 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2000 | 28 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2000 | 93 | 0.010 |
Why?
|
| DNA Primers | 1 | 2000 | 293 | 0.010 |
Why?
|
| Reference Values | 1 | 2000 | 335 | 0.010 |
Why?
|
| Vancomycin | 1 | 1999 | 39 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2000 | 200 | 0.010 |
Why?
|
| Mass Screening | 1 | 2004 | 687 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2000 | 276 | 0.010 |
Why?
|
| Virus Replication | 1 | 2000 | 319 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2004 | 2051 | 0.010 |
Why?
|
| Lactams | 1 | 1992 | 18 | 0.010 |
Why?
|
| Aminoglycosides | 1 | 1992 | 11 | 0.010 |
Why?
|
| United States | 1 | 2004 | 7749 | 0.010 |
Why?
|